Ectokinases as novel cancer markers and drug targets in cancer therapy

Author(s): Yalak, Garif; Vogel, Viola

Publication Date: 2015-03

Permanent Link: https://doi.org/10.3929/ethz-b-000093354


Rights / License: Creative Commons Attribution 4.0 International
Ectokinases as novel cancer markers and drug targets in cancer therapy

Garif Yalak¹,² & Viola Vogel²

¹Harvard Medical School/Harvard School of Dental Medicine, Department of Developmental Biology, Harvard University, Boston, Massachusetts 02115
²Laboratory of Applied Mechanobiology, Department of Health Sciences and Technology, ETH Zurich, Switzerland

Keywords
Cancer marker, drug design, ectokinases, exokinases, extracellular matrix, extracellular phosphorylation, extracellular protein kinase, personalized medicine

Correspondence
Viola Vogel, Laboratory of Applied Mechanobiology, Department of Health Sciences and Technology, ETH Zurich, Vladimir-Prelog-Weg 4, HCI F443, CH-8093 Zurich, Switzerland. Tel: +41 44 632 08 87; Fax: +41 44 632 10 73; E-mail: viola.vogel@hest.ethz.ch

Abstract
While small-molecule kinase inhibitors became the most prominent anticancer drugs, novel combinatorial strategies need to be developed as the fight against cancer is not yet won. We review emerging literature showing that the release of several ectokinases is significantly upregulated in body fluids from cancer patients and that they leave behind their unique signatures on extracellular matrix (ECM) proteins. Our analysis of proteomic data reveals that fibronectin is heavily phosphorylated in cancer tissues particularly within its growth factor binding sites and on domains that regulate fibrillogenesis. We are thus making the case that cancer is not only a disease of cells but also of the ECM. Targeting extracellular kinases or the extracellular signatures they leave behind might thus create novel opportunities in cancer diagnosis as well as new avenues to interfere with cancer progression and malignancy.

Introduction
Since the fight against cancer is far from being won, there is a need to think of new strategies to identify alternative targets for cancer diagnosis and combinatorial therapies. Current challenges include the desire to detect cancer much earlier, to prevent or reduce the emergence of acquired drug resistance [1], and to reduce the often
lethal side effects. Even more challenging is the fact that
different cancer cells from the same tumor can use differ-
ent pathways to achieve drug resistance [2]. The complex-
ity of pathways that can lead to drug resistance prevents
to predict which treatment modality might finally allow
the host rather the cancer to survive [3, 4]. Continued
chemotherapy will target only a subset of cancer cells,
while the resistant cells continue to grow [2]. New strate-
gies are therefore needed to target nonresistant and resis-
tant cancer cells. Protein phosphorylation is the key
regulatory posttranslational modification exploited for
intracellular signaling [5–7], and kinases require suffi-
ciently high ATP levels to transfer a phosphate group.
Today, it is believed that one third of human proteins are
phosphorylated [8] and small-molecule kinase inhibitors
have thus taken the lead as next generation cancer drugs
(Table 1) [9]. While this is a significant progress, these
inhibitors often interfere with other complex intracellular
signaling networks thus causing sometimes severe side
effects, and need to be combined with other approaches.

Cells secrete a cocktail of enzymes, such as cholinester-
ases, peptidases, transpeptidases, nucleotidases, phospho-
diesterasers, ectokinases, and ectophosphatases, which lead
to posttranslational modifications of extracellular matrix
(ECM) proteins, and the composition of this cocktail
depends on cell type, external stimulations, and disease
[10]. Posttranslational modifications of ECM proteins can
affect outside-in cell signaling and consequently cell
behavior [11]. The massive killing of cancer cells typically
increases the local extracellular concentrations of the cyto-
plasmic content, including ATP, thereby causing addi-
tional posttranslational modifications of the ECM. The
killing of cancer cells will thus leave behind a “diseased”
ECM that can send altered instructive signals to the cells
that later invade this cancerous ECM left behind. This has
not been considered in the treatment of cancer previ-
ously.

Beyond using the concentration of extracellular protein
kinases in blood to detect cancer in early stages [12–14],
ectokinases and ectophosphatases might serve as new drug
targets. Shielded by the plasma membrane, drugs with
extracellular targets might cause less side effects as they
can less directly interfere with intracellular signaling [15–
21]. Even though cancer is not only a disease of cells but
also leads to posttranslational modifications of the ECM,
the intracellular focus has overshadowed potential
extracellular opportunities that could be exploited to
address some of these challenges. Here, we thus review

Table 1. Small-molecule kinase inhibitors on the market against kinases.

<table>
<thead>
<tr>
<th>Name</th>
<th>Trade name</th>
<th>Targeted tyrosine kinase</th>
<th>Disease</th>
<th>Producer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imatinib</td>
<td>Gleevec, Glivec</td>
<td>BCR-Abl</td>
<td>Chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), number of other malignancies</td>
<td>Novartis</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>Iressa</td>
<td>EGFR</td>
<td>Breast, lung, other cancers</td>
<td>AstraZeneca, Teva</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>Tarceva</td>
<td>EGFR</td>
<td>Non-small cell lung cancer (NSCLC), pancreatic cancer, other types of cancer</td>
<td>Genentech, OSI Pharmaceuticals, Roche</td>
</tr>
<tr>
<td>Crizotinib</td>
<td>Xalkori</td>
<td>ALK</td>
<td>Non-small cell lung cancer (NSCLC)</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>Sprycel</td>
<td>BCR/Abl and Src family</td>
<td>Chronic myelogenous leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Tykerb/Tyverb</td>
<td>HER2 and EGFR</td>
<td>Breast cancer, other solid tumors</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Nilotinib</td>
<td>Tasigna</td>
<td>BCR-Abl, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFR8, MAPK11, and ZAK</td>
<td>Chronic myelogenous leukemia</td>
<td>Novartis</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>Votrient</td>
<td>c-KIT, FGFR, PDGFR, and VEGFR</td>
<td>Renal cell carcinoma, soft tissue sarcoma</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Sutent</td>
<td>PDGF-Rs, VEGFRs, KIT</td>
<td>Renal cell carcinoma (RCC), gastrointestinal stromal tumor</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Nexavar</td>
<td>VEGFR, PDGFR, Raf</td>
<td>Renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC), thyroid cancer</td>
<td>Bayer, Onyx Pharmaceuticals</td>
</tr>
<tr>
<td>Vandetanib</td>
<td>Caprelsa</td>
<td>VEGFR, EGFR, RET-tyrosine kinase</td>
<td>Tumors of the thyroid gland</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Xeljanz, Jakvinus</td>
<td>JAK</td>
<td>Rheumatoid arthritis</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Ruxolitinib</td>
<td>Jakafi, Jakavi</td>
<td>JAK</td>
<td>Myelofibrosis</td>
<td>Incyte Pharmaceuticals, Novartis</td>
</tr>
</tbody>
</table>

Current FDA-approved kinase inhibitors on the market in cancer treatment.

© 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 405
the indications that cancer is not only a disease of cells but also of the ECM, and how this newly emerging knowledge of extracellular posttranslational modifications can potentially be exploited for cancer diagnosis and treatment.

**Extracellular Enzymes and Posttranslational Modifications of ECM Coregulate Cancer Progression**

Extracellular strategies are mostly missing although considerable knowledge emerged that the composition and rigidity of the ECM, and consequently ECM cell signaling plays an important role in cancer progression [22, 23]. The first wave of targeting ECM enzymes was motivated by the finding that cancer tissues show upregulated matrix metalloproteinase (MMP) levels, and it was thought that MMP-induced cleavage of ECM would promote the escape of cancer cells from the site of tumors [24, 25] (Fig. 1A). Consequently, MMP inhibitors were designed and went into clinical trials, but with devastating negative outcomes [26, 27]. The main reason for the failure was the lack of appreciation for the complexity of MMP functions and their respective effects on ECM properties and signaling. Only three MMPs had been described at the time when the clinical trials had started, while 23 different MMPs are known today [28]. They were found in different cell types with diverse functions including ECM–cell interactions, cell–cell contact, and regulation of soluble factors among many others [27]. Broad-spectrum inhibitions of MMPs thus interfere with their diverse regulatory roles and thereby cause major side effects [29].

It is thus timely to consider alternate extracellular strategies, including extracellular enzymes or other means by which to regulate posttranslational modifications (Fig. 1B). While the importance of various posttranslational modifications in the ECM are known to regulate cancer progression [23], the significance of ectokinases and ectophosphatases, and the signatures they leave behind, is only now at the verge of being recognized [30]. Why should we even consider extracellular phosphorylation since the ATP levels are typically low in extracellular environment? Extracellular ATP can transiently increase to levels that are sufficiently high to activate ectokinases in those tissues that undergo major necrosis and apoptosis, thereby releasing intracellular content [30]. Also ATP secretion pathways are significantly upregulated in cancers [31, 32] and increased levels of extracellular ATP could recently been measured at tumor sites [33].

Among the reported ectokinases, the most prominent ones are the casein kinase II (CKII) [34], protein kinase A (PKA) [35], protein kinase C (PKC) [36], and the
recently reported Fam20C kinase [37]. Several ectophosphatases including alkaline phosphatase [38], tartrate-resistant acid phosphatase (TRAP) [39], and the most recently reported PTEN phosphatase [40] have been reported in the ECM. Interestingly, the concentration of the extracellular alkaline phosphatase is already measured routinely as a disease marker in patient’s blood samples to detect liver diseases, bone disorders, or cancer and the TRAP is being discussed as a good candidate [39, 41].

Taken together, considerable evidence is emerging that posttranslational modifications of ECM coregulate cancer progression, that ectokinases and ectophosphatases are found in body fluids of cancer patients, and that kinases can be transiently active in extracellular space in regions where necrosis or other factors cause the release of ATP. As with any discovery, new ideas and strategies are thus beginning to emerge how to exploit these emerging insights into early cancer detection and therapy.

**Striking Signatures of Extracellular Kinase Activity Are Found in Cancer Tissues**

Postulating that massive necrosis might temporarily upregulate ectokinease activity in extracellular space, we recently mined published proteomic data and found a significant upregulation of phosphorylated residues in tissue samples from cancer patients [30]. This included the
phosphorylation of ECM proteins, as well as of cell surface and extracellular domains of transmembrane proteins. Screening more than 60 different extracellular proteins revealed that nearly all can occur in phosphorylated states [30]. Most compelling was the finding that the integrin subunits $\alpha_4$ and $\beta_1$, two key players in cancer progression and signaling, were found in tissue samples to be phosphorylated in their extracellular domains [30, 42–44]. Since fibronectin [45–47] which is a key component of the ECM is known to be highly upregulated in cancer [48–53], we further analyzed published proteomic data and found that fibronectin is indeed heavily phosphorylated in clinical cancer tissue samples (Fig. 2, Table 2). Heavily phosphorylated regions in fibronectin include and are associated with growth factor binding sites (FnIII4, FnIII13-14) and with domains that regulate fibronectin fibrillogenesis. This is an important finding since growth factor signaling and ECM fibrillogenesis are essential regulators in cancer malignancy and progression [22]. In addition to fibronectin, elevated levels of phosphorylated fibrinogen A are found in the plasma from patients with stage III or IV ovarian cancer compared to healthy controls [54].

Taken together, available data suggest that the upregulated phosphorylation of fibronectin and of some other extracellular proteins is a distinct signature of cancerous ECM. The phosphorylation of the ECM caused by the transient release of ATP by dying cells might thus be physiologically far more important in regulating cancer cell differentiation and tumor progression than previously thought. Indeed, the phosphorylation ratio of peptides increase with tumor size as has been previously shown [13]. Any discovery of new signatures how cancer or cancer tissues are different from the norm might offer valuable entrance points for novel diagnostic or therapeutic strategies. Furthermore, extracellular proteins that are highly phosphorylated in some but not in other cancer types might be suitable as novel markers for the early detection of cancers, or perhaps serve as signature of its malignancy.

**New Strategies for Cancer Diagnostics: Quantification of the Concentrations and Activities of Extracellular Protein Kinases**

One major challenge is to detect cancer in earlier stages in order to treat patients more successfully. According to recent cancer statistics, the 5-year survival rate dramatically drops if cancer is detected at a late stage [55]. Most of the current serum tumor markers are based on the antigen determination method, including CEA, AFP, hCG, PSA, and CA125, but lack tumor specificity and often cannot be used in early cancer.
## Table 2. Experimentally verified phosphorylation sites on fibronectin in cancer samples.

<table>
<thead>
<tr>
<th>Residue (P02751)</th>
<th>Location/binding sites</th>
<th>Reference/databases</th>
<th>Cancer tissues/cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y101, Y106, T136</td>
<td>FnII2, Fn–Fn, Heparin, Tenascin, Fibrin</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In seven patients samples (Y101): ovarian, liver, lung, esophageal, gastric</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patient sample (Y106): ovarian</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patient sample (T136): T-cell leukemia</td>
</tr>
<tr>
<td>Y372</td>
<td>FnII1, Collagen, Gelatin</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In three patients samples: ovarian, liver, hepatocellular carcinoma, hepatocyte–liver</td>
</tr>
<tr>
<td>Y588</td>
<td>FnIII9, Collagen, Gelatin</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In one patients sample: lung carcinoma</td>
</tr>
<tr>
<td>Y641</td>
<td>FnIII1, Fn–Fn</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In one patients sample: pancreatic carcinoma</td>
</tr>
<tr>
<td>S904</td>
<td>Linker FnIII3-FnIII4</td>
<td>Phosida, PhosphositePlus, PhosphoNet, HPRD, dbPTM [79]</td>
<td>HeLaS3 (cervical cancer)</td>
</tr>
<tr>
<td>S909</td>
<td>FnIII4, DNA binding</td>
<td>HPRD, dbPTM [80]</td>
<td>Hela cells</td>
</tr>
<tr>
<td>Y937, T960, S968, T972</td>
<td>FnIII4, DNA binding</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In one patients sample (Y037): gastric</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patients sample (T960): T-cell leukemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patients sample (S968): T-cell leukemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patients sample (T972): T-cell leukemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Embryonic stem cells</td>
</tr>
<tr>
<td>Y1042</td>
<td>FnIII5</td>
<td>PhosphositePlus, PhosphoNet, dbPTM [81]</td>
<td>In two patients samples: ovarian</td>
</tr>
<tr>
<td>Y1206</td>
<td>FnIII7</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In one patients sample: colorectal</td>
</tr>
<tr>
<td>T1271</td>
<td>FnIII8, Cell binding region</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>293 (epithelial)</td>
</tr>
<tr>
<td>T1462</td>
<td>FnIII10, Cell binding region</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In one patients sample (T1462): esophageal</td>
</tr>
<tr>
<td>T1743, T1762, T1786, S1833, T1840, T1842, T1855, T1860, Y1879, Y1884</td>
<td>FnIII13, Heparin, Syndecan-4</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In one patients sample (T1743): T-cell leukemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patients sample (T1762): esophageal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patients sample (T1786): esophageal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patients sample (S1833): liver, cholangiocellular carcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In two patients samples (1840): cervical</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patients sample (T1842): cervical</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In two patients samples (T1855): cervical</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patients sample (T1860): cervical</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In one patients sample (Y1879): ovarian</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In two patients samples (Y1884): ovarian, T-cell leukemia</td>
</tr>
<tr>
<td>S2007</td>
<td>Variable region IIICS, LDV, REDV integrin binding sites</td>
<td>Phosida [83]</td>
<td>Hela cells</td>
</tr>
<tr>
<td>S2131, S2139</td>
<td>FnIII15, Cryptic cysteine</td>
<td>[84]</td>
<td>U266 (immortal B lymphocytes derived from multiple myeloma)</td>
</tr>
<tr>
<td>S2174</td>
<td>FnIII15, Cryptic cysteine</td>
<td>Phosida, [83, 85, 86]</td>
<td>Hela cells, HEK, human liver tissue</td>
</tr>
<tr>
<td>S2182, S2209</td>
<td>FnIII15, Cryptic cysteine</td>
<td>Phosida [83]</td>
<td>Hela cells</td>
</tr>
<tr>
<td>S2251</td>
<td>FnIII10, Fibrin binding</td>
<td>[84]</td>
<td>U266 (immortal B lymphocytes derived from multiple myeloma)</td>
</tr>
<tr>
<td>Y2258</td>
<td>FnI11</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In one patients sample: ovarian</td>
</tr>
<tr>
<td>S2259, S2285, S2293</td>
<td>FnI11, Fibrin binding, Protein–disulfide isomerase binding</td>
<td>[84]</td>
<td>U266 (immortal B lymphocytes derived from multiple myeloma)</td>
</tr>
<tr>
<td>S2294</td>
<td>FnI12, Fibrin binding, Protein–disulfide isomerase binding</td>
<td>Phosida, [83, 85, 86]</td>
<td>Hela cells, HEK, human liver tissue</td>
</tr>
<tr>
<td>S2318</td>
<td>FnI12, Fibrin binding, Protein–disulfide isomerase binding</td>
<td>dbPTM [84]</td>
<td>U266 (immortal B lymphocytes derived from multiple myeloma)</td>
</tr>
<tr>
<td>S2328</td>
<td>FnI12, Fibrin binding, Protein–disulfide isomerase binding</td>
<td>Phosida, [83, 85, 86]</td>
<td>Hela cells, HEK, Human liver tissue</td>
</tr>
<tr>
<td>S2341, S2349</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>dbPTM, [84]</td>
<td>Serum</td>
</tr>
<tr>
<td>Y2350</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>PhosphositePlus, PhosphoNet</td>
<td>In two patients samples: breast, ovarian</td>
</tr>
<tr>
<td>Y2353</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>PhosphoNet, PhosphositePlus [87]</td>
<td>In 12 patient samples, breast, lung, gastric, liver, hepatocellular carcinoma</td>
</tr>
</tbody>
</table>
screening and diagnosis [56–63]. To overcome these shortcomings, novel, cheap, and fast diagnostic tools need to be developed. Measurements of ectokinase and ectophosphatase concentrations and activities in serum might thereby provide new opportunities (Fig. 3). Such measurements could be embedded in routinely performed blood tests to screen for cancer long before patients show symptoms. Recent studies with more than 600 patients (374 healthy controls, 229 cancer patients) showed a significant upregulation of ecto-PKA concentrations in serum of cancer patients in contrast to healthy controls [64]. While more than 70% of the control patients had undetectable or low ecto-PKA concentrations in serum, more than 85% of the cancer patients had high levels of PKA concentrations, with average activity fivefold higher compared to the healthy controls. In another independent study, sera of 500 patients (295 various cancers, 155 normal controls, 55 without cancer) were analyzed by autoantibody against ecto-PKA. The presented anti-ecto-PKA measurement showed a 90% sensitivity and 80% specificity compared to the conventional methods with 83% sensitivity and 80% specificity [65]. Only recently, the quantification of ecto-PKA has been patented as a cancer marker for prostate and breast cancer [66]. As suggested by the research group, this approach has the potential to replace the commonly used PSA screening test for prostate cancer and the mammograms screening test for breast cancer, which cost nearly $6 billion annually in the United States alone, with limited reliability of the outcome [67–69]. Alternatively or in combination, the ecto-PKC and ecto-CKII are other kinases well suited for phenotyping as they are reported in the ECM and show upregulated levels in secretory vesicles of prostate cancer samples [36, 70]. Such a path holds considerable promise particularly since a 10-fold increased abundance of ecto-PKC in serum of cancer patients with renal, colon, rectal, adrenal, and lung cancer compared to normal serum has recently been reported [71].

**New Strategies for Cancer Treatment:**

**Drug Targeting of Extracellular Protein Kinases and Phosphatases**

In the last two decades, intracellular protein kinases have emerged as the most important drug targets in pharmaceutical industry leading to some 20 approved drugs on the market and hundreds more in clinical trials [72]. To reduce side effects, a combinatorial approach is needed, one targeting and killing cancer cells while one also tries to prevent or revert the diseased state of ECM. One can further speculate that these drugs might have less side effects as they will not directly interfere with intracellular signaling events [73], but are expected to regulate primarily outside-in cell signaling. Since several important intracellular protein kinases and phosphatase including PKA, PKC, CKII, FAM20C, alkaline phosphatase, and PTEN phosphatase have been found as ectokinases and ectophosphatases, especially in cancer malignancy and progression [30], their potential as novel drug targets has been highlighted [74, 75], but not yet systematically

### Table 2. Continued.

<table>
<thead>
<tr>
<th>Residue (P02751)</th>
<th>Location/binding sites</th>
<th>Reference/databases</th>
<th>Cancer tissues/cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2353</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>Phosida, [83, 85, 86]</td>
<td>Hela cells, HEK, human liver tissue</td>
</tr>
<tr>
<td>S2354</td>
<td>C-terminus</td>
<td>PhosphositePlus, PhosphoNet [84]</td>
<td>In one patient sample: ovarian cancer U266 (immortal B lymphocytes derived from multiple myeloma)</td>
</tr>
<tr>
<td>S2376</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>Phosida, PhosphoSitePlus, PhosphoNet, dbPTM, UniProt, [83, 84, 86, 88–90]</td>
<td>In 14 patients samples: breast, skin, liver, hepatocellular carcinoma, and surrounding tissue, blood plasma U266 (immortal B lymphocytes derived from multiple myeloma), Hela cells</td>
</tr>
<tr>
<td>S2384</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>[83, 85, 86]</td>
<td>Hela cells, HEK, human liver tissue</td>
</tr>
<tr>
<td>S2419</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>[83, 85, 86]</td>
<td>Hela cells, HEK, human liver tissue</td>
</tr>
<tr>
<td>S2432, S2440</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>HPRD [84]</td>
<td>U266 (immortal B lymphocytes derived from multiple myeloma)</td>
</tr>
<tr>
<td>S2444</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>Phosida [83]</td>
<td>Hela cells</td>
</tr>
<tr>
<td>S2475</td>
<td>C-terminus, Disulfide bonds for Fn assembly</td>
<td>HPRD [83, 85, 86]</td>
<td>Hela cells, U266 (immortal B lymphocytes derived from multiple myeloma)</td>
</tr>
</tbody>
</table>

Phosphorylated sites by mass spectrometry retrieved from protein databases. Due to lack of track changes and updates of the databases, the reported sites here may differ from the database entries at later points. Table as of Nov. 2014.
exploited. The overexpression of ecto-PKA in secretory vesicles in prostate cancer further points to a putative regulatory role of ectokinases in cancer [70]. The expression of the ecto-PKA kinase, as probed in serum of melanoma patients, correlated with the appearance and size of the tumor and tumor removal reduced the levels of ecto-PKA [14]. Ecto-PKC is another kinase that has been reported to be present and active in sera of cancer patients with renal, colon, rectal, adrenal, and lung cancer [36, 71]. Both ecto-PKC and ecto-CKII have been reported to be expressed in secretory vesicles in prostate cancer and they might thus serve as novel targets [70]. The role for FAM20C kinase [37], which is present and active in the ECM, is already discussed in the regulation of bone metastasis [76].

Besides protein kinases, protein phosphatases could also serve as potential drug targets. Most recently, monoclonal antibodies were designed to target the extracellular alkaline phosphatase that is expressed on the surface of gastrointestinal cancer cells [77]. In addition, the PTEN phosphatase, a tumor suppressor that is known to induce tumor cell death in vitro and in vivo, has been reported to be secreted and subsequently enter other cells where it modifies their signaling and survival [40]. Finally, mutations in PTEN and their down regulation are reported to be involved in invasion and metastasis of colorectal carcinomas, indicating PTEN as a novel drug target and a marker for colorectal carcinoma [78]. Another advantage is that ectokinases and ectophosphatases could be targeted in cases where other drugs are not efficient anymore due to resistance of the tumor. Consequently, selected extracellular protein kinases and phosphatases might be good candidates for the development of novel drug targets.

**Future Perspectives**

As extracellular protein phosphorylation is moving into the spotlight of attention, our goal here is to stimulate a thinking process how to best utilize this information for the fight of cancer. An increased understanding of the role of ectokinases and ectophosphatases in the regulation of outside-in signaling pathways in cancer malignancy and progression might result not only in exciting new science but also in the design of new combinatorial drugs that can display their functions in extracellular space [15–21], perhaps complementing conventional therapies, by modulating outside-in cell signaling through the posttranslational modification of extracellular proteins. Starting to apply the knowledge gained in the last 60 years about intracellular protein kinases to the extracellular space offers new opportunities. Ultimately, we need to learn not only how to effectively kill cancer cells but also how to repair diseased cancerous ECM that is left behind and has the potency to send altered instructive signals to newly invading cells.

**Acknowledgments**

This work was supported by the ERC Advanced Grant (European Research Council, Contract Nr. 233157, V. V.), CCMX Competence Centre for Materials Science and Technology, Grant 0-21108-10, the Swiss Initiative in Systems Biology (SystemsX.ch, "Phosphorylation Modulated Networks of the Cell" [PhosphoNetX]), the Swiss National Science Foundation (SNF, Contract Nr. 3100A0-116236), the Swiss National Science Foundation (Postdoctoral fellowship PBEZP3_145998 to G. Y.), and by the ETH Zurich.

**Conflict of Interest**

None declared.

**References**


